Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qishen Huoxue Granules (QHG) is a classical Traditional Chinese Medicine (TCM) prescription formulated as a botanical drug. It is primarily used for the treatment of cardiovascular diseases, especially chronic heart failure and sepsis-induced cardiomyopathy. The formulation contains multiple herbal components designed to achieve synergistic therapeutic effects by improving myocardial energy metabolism and alleviating symptoms associated with heart failure[2][3][5]. Mechanistically, recent studies indicate that QHG exerts its effects by modulating the Mas receptor/PI3K-AKT-mTOR signaling pathway, thereby inhibiting excessive autophagy in cardiomyocytes and reducing cardiac damage during sepsis[6]. Clinical trials have shown that it can reduce NT-proBNP levels in patients with chronic heart failure and improve functional outcomes such as exercise capacity and quality of life when used alongside standard therapy[2]. Adverse reactions are mainly gastrointestinal but are generally comparable to placebo. The product is under investigation for additional indications such as coagulopathy/early DIC in sepsis[7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qishen Huoxue Granules.